Entest BioMedical's Zander Therapeutics Unit Files Patent Application on Ex Vivo Activated Autologous Immune Cells
Entest BioMedical Inc.'s (OTC: ENTBD) Zander Therapeutics unit announced today its personalized canine cancer immune therapy platform and proof-of-concept experimental data. The data on which this provisional patent was based came from previous research conducted by Thomas Ichim, PhD, a scientific consultant to Zander. On July 31, 2015, Zander filed a provisional patent application with the United States Patent Office (USPTO) on intellectual property in the veterinary oncology space.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is wholly owned by Entest BioMedical Inc. a fully reporting and trades publicly under the symbol: ENTB Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017